How Investors May Respond To Ultragenyx (RARE) EMA Review Starts

Ultragenyx Pharmaceutical (RARE) shares rose 3.2% after agreeing to sell a Rare Pediatric Disease Priority Review Voucher for $210M, awarded following FDA approval of GENGLYCOS for glycogen storage disease. The company plans to use proceeds to support rare disease therapy development and advance profitability, according to Ultragenyx.

Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $210M, according to the company. Proceeds will support rare-disease programs. RARE shares rose 4% at the time of writing, despite broader market declines. This is Ultragenyx's third PRV sale, with previous sales in 2018 totaling $210.6M.

Ultragenyx (RARE) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210M. 20% of proceeds will go to NIH. The deal is subject to closing conditions and will provide immediate cash. The buyer is undisclosed.

Ultragenyx (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210M, received after FDA approval of GENGLYCOS. The deal, advised by Jefferies, aims to support the company's profitability path. The transaction is pending regulatory approval.

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210M. The voucher was received after FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The deal, subject to closing conditions, will provide non-dilutive capital to advance rare disease therapies and support profitability. Jefferies LLC and Gibson Dunn are advising Ultragenyx.

Ultragenyx Pharmaceutical (RARE) announced EMA validation of its MAA for rebisufligene etisparvovec, a gene therapy for MPS IIIA. The validation allows the EMA to begin its review. The therapy has received PRIME and Orphan Drug designations. RARE shares closed at $14.75, up 0.59% in premarket trading.